Study S000051

A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00775684
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: COMPLETED
Enrollment: 47
Start: 2008-10
Primary completion: 2012-11
Lead sponsor: University of Pennsylvania
Conditions: Pre-diabetes; Type 2 Diabetes
Interventions: DRUG:Exenatide; DRUG:Sitagliptin; DRUG:Glimepiride
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (μU/ml) [Baseline and 6 months]
Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (pg/mL) [Baseline and 6 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.